Literature DB >> 29473130

Percutaneous endoscopic gastrostomy site infections-Incidence and risk factors.

Kayal Vizhi1, Harshavardhan B Rao2, Rama P Venu1.   

Abstract

BACKGROUND: Percutaneous endoscopic gastrostomy (PEG) placement is the modality of choice for long-term enteral nutrition in view of technical ease and cost-effectiveness. Peristomal infection (PI) remains the most common complication following PEG tube placement. The aim of this study was to assess the incidence and risk factors for PI and outline a microbiological profile that can aid in prophylactic and therapeutic strategies.
METHODS: A retrospective study of 781 patients who underwent PEG placement (Cook PEG-Pull-S-20Fr/24Fr) from 2010 to 2015 at our tertiary care center were included. Relevant data were collected from the hospital electronic medical records. The incidence of PI was computed and potential risk factors were assessed using univariate analysis. The microbiological profile was created along with sensitivity patterns after reviewing the culture reports. Statistical analysis was performed using SPSS version 20.0.
RESULTS: PEG tube placement was performed in 781 patients (mean age 55.9 ± 36.1; M:F = 2:75). The major indication was oropharyngeal malignancies. PI was seen in 171 patients (21.9%). Diabetes mellitus, duration of hospital stay more than 7 days, and hypoalbuminemia were found to be significant risk factors for the development of PI (p < 0.05). Patients who had chemotherapy or radiotherapy before PEG placement had a higher incidence of peristomal infections (p 0.00). Pseudomonas and Klebsiella were the most common organisms causing infection.
CONCLUSIONS: PI remains a significant complication of PEG placement. Pseudomonas and Klebsiella are the most common organisms and prophylactic antibiotic protocols should be tailored accordingly. Elective PEG before the institution of chemotherapy/radiotherapy in patients with oropharyngeal malignancies is recommended.

Entities:  

Keywords:  Complications; Endoscopic; Enteral; Gastrostomy; Infections; Nutrition; Percutaneous endoscopic gastrostomy

Mesh:

Substances:

Year:  2018        PMID: 29473130     DOI: 10.1007/s12664-018-0822-4

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  25 in total

1.  Antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): a prospective randomized clinical trial.

Authors:  L Gossner; J Keymling; E G Hahn; C Ell
Journal:  Endoscopy       Date:  1999-02       Impact factor: 10.093

Review 2.  Complications of enteral access.

Authors:  Stephen A McClave; Wei-Kuo Chang
Journal:  Gastrointest Endosc       Date:  2003-11       Impact factor: 9.427

3.  Antibiotic prophylaxis in percutaneous endoscopic gastrostomy.

Authors:  T M Sturgis; W Yancy; J C Cole; D D Proctor; B S Minhas; S P Marcuard
Journal:  Am J Gastroenterol       Date:  1996-11       Impact factor: 10.864

Review 4.  Percutaneous endoscopic gastrostomy.

Authors:  B Y Safadi; J M Marks; J L Ponsky
Journal:  Gastrointest Endosc Clin N Am       Date:  1998-07

5.  Percutaneous endoscopic gastrostomy (PEG) site infections: a clinical and microbiological study from university teaching hospital, India.

Authors:  Sushma Krishna; Sanjeev Singh; Kavitha R Dinesh; Remya Kp; Ismail Siyad; Shamsul Karim
Journal:  J Infect Prev       Date:  2014-12-10

6.  Effect of antibiotic prophylaxis in percutaneous endoscopic gastrostomy.

Authors:  S K Jonas; S Neimark; A P Panwalker
Journal:  Am J Gastroenterol       Date:  1985-06       Impact factor: 10.864

7.  Antibiotic prophylaxis for percutaneous endoscopic gastrostomy. A prospective, randomized, double-blind clinical trial.

Authors:  N K Jain; D E Larson; K W Schroeder; D D Burton; K P Cannon; R L Thompson; E P DiMagno
Journal:  Ann Intern Med       Date:  1987-12       Impact factor: 25.391

8.  Percutaneous endoscopic gastrostomy. Indications, success, complications, and mortality in 314 consecutive patients.

Authors:  D E Larson; D D Burton; K W Schroeder; E P DiMagno
Journal:  Gastroenterology       Date:  1987-07       Impact factor: 22.682

9.  Peristomal infection after percutaneous endoscopic gastrostomy: a 7-year surveillance of 297 patients.

Authors:  Helena Duarte; Carla Santos; Manuel Luís Capelas; Jorge Fonseca
Journal:  Arq Gastroenterol       Date:  2012-12

10.  Enteral long-term nutrition via percutaneous endoscopic gastrostomy (PEG) in 210 patients: a four-year prospective study.

Authors:  C Löser; S Wolters; U R Fölsch
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

View more
  5 in total

Review 1.  Prevention and management of minor complications in percutaneous endoscopic gastrostomy.

Authors:  Kurt Boeykens; Ivo Duysburgh; Wim Verlinden
Journal:  BMJ Open Gastroenterol       Date:  2022-07

2.  Prediction of risk of adverse events related to percutaneous endoscopic gastrostomy: a retrospective study.

Authors:  Maha Osman Mohamed Shangab; Niaz Ahmed Shaikh
Journal:  Ann Gastroenterol       Date:  2019-07-25

3.  Clinical and Pathologic Profiles of Esophageal Cancer in Mozambique: A Study of Consecutive Patients Admitted to Maputo Central Hospital.

Authors:  Jotamo Come; Clara Castro; Atílio Morais; Matchecane Cossa; Prassad Modcoicar; Satish Tulsidâs; Lina Cunha; Vitória Lobo; Alberto Gudo Morais; Sofia Cotton; Nuno Lunet; Carla Carrilho; Lúcio Lara Santos
Journal:  J Glob Oncol       Date:  2018-11

4.  Clinical characteristics and pathogens in percutaneous endoscopic gastrostomy site infection in patients with head and neck cancer: A 16-year retrospective study.

Authors:  Jihyu Oh; So Yeon Park; Jin Seo Lee; Ji-Young Park; Seo Hu Lee
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-09-29

5.  The complication rate, but not the mortality rate, lower after percutaneous endoscopic gastrostomy than after open surgical gastrostomy: comparison of two methods in a high volume group of patients.

Authors:  Gustaw Lech; Waldemar Pawłowski; Wojciech Korcz; Tomasz Guzel; Bohdan Dąbrowski; Andrzej Opuchlik; Dominika Głąbska; Maciej Słodkowski
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2022-09-07       Impact factor: 1.627

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.